Mariana Oncology is focused on advancing precision radiopharmaceuticals to treat cancer.

Mariana Oncology

Mariana Oncology | 6,251 followers on LinkedIn. Driven to Cure: Delivering innovative, safe and effective radiopharmaceutical care for solid cancers | Mariana Oncology, a Novartis company, is a fully integrated next generation radiopharmaceutical company that brings together experts in ligand discovery, radiochemistry, radiobiology and oncology translational and clinical research in order to build a pipeline across a range of solid tumor types. Our mission at Mariana is to discover and develop safe, effective, and highly targeted radiopharmaceuticals.

IT/Informatics | AWS Certified Solutions Architect | Data Privacy/Security

Mark Duffield

Executive Business Partner

Allison Lenz

Toommy Becker

Alok Singh

Our team enjoyed taking in pioneering research and engaging in conversations with peers advancing new approaches to radiopharmaceuticals, imaging agents, and detection technologies to improve the treatment of cancer and other serious diseases this week at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) . #MarianaOnTheMove #Oncology #RadioligandTherapies #RLT

Visit our poster today at the 36th EORTC - European Organisation for Research and Treatment of Cancer - National Cancer Institute (NCI) - American Association for Cancer Research Symposium where we’re sharing preclinical data that confirms our DLL3-targeted radioligand therapy is active against DLL3, including in tumor models exhibiting low DLL3 expression. The results further support its potential to address a range of solid tumor indications as a novel treatment option. (Poster ENA24-152) #ENA2024 #RLT #radioligandtherapy #oncology

Our novel, DLL3-targeted radioligand therapy is designed for potential high, rapid tumor uptake and retention, and fast clearance of unbound molecules. Today at the ESMO - European Society for Medical Oncology Congress 2024, we’re presenting preclinical results that characterize in vitro and in vivo properties of our experimental treatment. (Poster #1153P ) #ESMO2024 #RLT #radioligandtherapy #oncology

Mariana Oncology today announced the company will be acquired by Novartis for up to $1.75B. Together, we will accelerate the development and delivery of precision radioligand therapeutics – therapies with the potential to transform the standard of care for people living with cancer. Read more about the exciting news here: https://lnkd.in/geVhN7RG

Meet the visionary force behind our scientific endeavors, Alonso Ricardo ! As our Chief Scientific Officer, he brings cutting-edge expertise and innovation to our research journey. Alonso has over a decade of drug discovery and development experience leading scientific programs across multiple therapeutic programs including immunology, metabolic diseases, and oncology. We are glad to have you on #TeamMariana , Alonso. Your commitment is truly appreciated! Stay tuned for more leadership team spotlights!

Did you know that the choices we make every day can lower our risk for different types of #cancer ? Research shows that up to 50% of cancer cases and about 50% of cancer deaths are preventable with the knowledge we have today. At Mariana, we are not only dedicated to transforming cancer treatment, but the experience of cancer care for people living with this disease, helping to maintain quality of life throughout a person’s cancer journey. Learn more here: www.marianaoncology.com And join us in celebrating #NationalCancerPreventionMonth by learning more about how to reduce your cancer risk and detect cancer early. Visit https://lnkd.in/gT2vd6hZ

MARI

COM:MARIANAONCOLOGY

Mariana Oncology